Search
Dementia Paid Clinical Trials in Florida
A listing of 41 Dementia clinical trials in Florida actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 41
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Dementia
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Florida currently has 41 active clinical trials seeking participants for Dementia research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Salivary Biomarkers for People with Frontotemporal Dementia (FTD)
Recruiting
Participants for this study included anyone ages 45 to 85+ years of age with Frontotemporal Dementia (FTD). In this research study, you will be potentially required to give a saliva sample. This saliva sample will be obtained by a cotton pad being placed within the participant's mouth absorbing the saliva. In addition, Prior to the salivary collection, you will be potentially asked to take a general survey about your diagnosis and other health questions to verify if you fit the criteria for the study. The purpose of this study is to provide insight into how we can use the proteins Tau and TDP-43 can be used to identify Frontotemporal Dementia early. Another important aspect of this research is to create a non-invasive biomarker using saliva that can benefit the efficiency of identifying disease
Conditions:
Frontotemporal Dementia
Frontotemporal Degeneration
FTD
Frontotemporal Dementia (FTD)
Frontal Temporal Dementia (FTD)
Featured Trial
Mild To Moderate Alzheimer's Disease Study
Recruiting
Join the effort to help research an investigational drug for Alzheimer's Disease. Those who qualify may receive:
o Compensation for time
o Reimbursement for study-related travel
o Study-related care from local doctors
o Study drug
o Compensation for time
o Reimbursement for study-related travel
o Study-related care from local doctors
o Study drug
Conditions:
Alzheimer Disease
Alzheimer's Disease
Alzheimer Dementia
Dementia Alzheimers
Dementia
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/21/2024
Locations: Hialeah, Florida, Hialeah, Florida
Conditions: Healthy Participants, Alzheimer's Disease Dementia
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Mayo Clinic, Jacksonville, Jacksonville, Florida +2 locations
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Recruiting
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.
To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB.
Clinicians use the C... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/18/2024
Locations: Charter Research, LLC, Lady Lake, Florida +4 locations
Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Bay Pines VA, Bay Pines, Florida +5 locations
Telehealth in Lewy Body Dementia
Recruiting
Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/28/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Lewy Body Dementia With Behavioral Disturbance, Lewy Body Parkinson Disease, Lewy Body Disease
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
05/24/2024
Locations: JEM Research Institute, Atlantis, Florida +22 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: Neurology of Central Florida Rsch Ctr Site #803, Altamonte Springs, Florida +93 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Recruiting
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.... Read More
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/22/2024
Locations: k2 Medical Research-Maitland, Maitland, Florida +1 locations
Conditions: Frontotemporal Dementia
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Recruiting
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
05/22/2024
Locations: Boca Raton, Florida, Boca Raton, Florida +7 locations
Conditions: Apathy in Dementia
Clinical Procedures to Support Research in ALS
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Anti-Diabetic Medications to Fight PD and LBD
Recruiting
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
Gender:
All
Ages:
Between 45 years and 65 years
Trial Updated:
05/17/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Lewy Body Dementia, Parkinson Disease
Life's End Benefits of Cannabidiol and Tetrahydrocannabinol
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks.
This study will enroll approximat... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
05/16/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Agitation, Dementia
1 - 12 of 41